MCID: OPD001
MIFTS: 40

Opioid Abuse malady

Categories: Mental diseases

Aliases & Classifications for Opioid Abuse

Summaries for Opioid Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of opioid drugs despite negative consequences.

MalaCards based summary : Opioid Abuse is related to cervicitis and chronic pain. An important gene associated with Opioid Abuse is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and VEGF Pathway (Qiagen). The drugs Buprenorphine and Heroin have been mentioned in the context of this disorder. Affiliated tissues include heart, b cells and brain, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Opioid Abuse

Graphical network of the top 20 diseases related to Opioid Abuse:



Diseases related to Opioid Abuse

Symptoms & Phenotypes for Opioid Abuse

MGI Mouse Phenotypes related to Opioid Abuse:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.92 CCK CCKAR CCKBR DRD2 GRIN3B MAPK10
2 homeostasis/metabolism MP:0005376 9.7 CCK CCKAR CCKBR DRD2 MAPK10 OPRM1
3 digestive/alimentary MP:0005381 9.65 CCKAR CCKBR DRD2 OPRM1 PDYN
4 nervous system MP:0003631 9.5 CCK CCKAR CCKBR DRD2 MAPK10 OPRM1
5 no phenotypic analysis MP:0003012 9.02 MAPK10 OPRM1 PDYN CCK DRD2

Drugs & Therapeutics for Opioid Abuse

Drugs for Opioid Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 301)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 52485-79-7 40400 644073
2
Heroin Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 561-27-3 5462328
3
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
4
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 76-99-3 4095
5
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2 249296-44-4 5310966
6
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983
7
Clonidine Approved Phase 4,Phase 3,Phase 2,Phase 1 4205-90-7 2803
8
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
9
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
10
Tramadol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 27203-92-5 33741
11
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-36-2 5760 446220
12
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 465-65-6 5284596
13
Amphetamine Approved, Illicit Phase 4,Phase 1 300-62-9 5826 3007
14
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
15
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1 64-17-5 702
16
Hydrocodone Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 125-29-1 5284569
17
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 57-27-2 5288826
18
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 16590-41-3 5360515
19
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 76-42-6 5284603
20
Dextromethorphan Approved Phase 4,Phase 3,Phase 2,Phase 1 125-71-3 5360696 5362449
21
Hydromorphone Approved, Illicit Phase 4,Phase 3,Phase 1,Phase 2 466-99-9 5284570
22
Phenobarbital Approved Phase 4 50-06-6 4763
23
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
24
Ketamine Approved, Vet_approved Phase 4,Phase 2 6740-88-1 3821
25
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 113-45-1 4158
26
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
27
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
28
Ribavirin Approved Phase 4 36791-04-5 37542
29
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
30
Oxymorphone Approved, Investigational, Vet_approved Phase 4,Phase 3 76-41-5 5284604
31
Gabapentin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 60142-96-3 3446
32
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
33
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
34
Acetazolamide Approved, Vet_approved Phase 4,Phase 2 59-66-5 1986
35
Loperamide Approved Phase 4 53179-11-6 3955
36
Opium Approved, Illicit Phase 4 8008-60-4
37
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
38
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
39
Pantoprazole Approved Phase 4 102625-70-7 4679
40 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
41 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Narcotic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Narcotics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Antitussive Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Phase 2,Phase 1
49 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 561)
id Name Status NCT ID Phase
1 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4
2 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
3 Smoking Cessation Treatment for Methadone Maintenance Patients Unknown status NCT01027754 Phase 4
4 Epidural Analgesia for Pancreatitis (Epipan Study) Unknown status NCT02126332 Phase 4
5 The Maternal Lifestyle Study (MLS) Completed NCT00059540 Phase 4
6 Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population Completed NCT02038790 Phase 4
7 A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine Completed NCT00314340 Phase 4
8 Pre-Release VIVITROL for Opioid Dependent Inmates Completed NCT01563718 Phase 4
9 Abuse Liability of Controlled-Release Oxycodone Formulations Completed NCT02101840 Phase 4
10 Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED) Completed NCT00684073 Phase 4
11 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
12 Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14 Completed NCT00015340 Phase 4
13 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
14 Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza Completed NCT00640042 Phase 4
15 Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME") Completed NCT00955162 Phase 4
16 Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment Completed NCT02032433 Phase 4
17 Feasibility Study of Take-Home LAAM Medication - 3 Completed NCT00000300 Phase 4
18 Effects of Buspirone in Opiate Withdrawal Completed NCT00326235 Phase 4
19 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
20 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4
21 Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms Completed NCT01502644 Phase 4
22 Relapse Prevention to Reduce HIV Among Women Prisoners Completed NCT00763958 Phase 4
23 Fast-Release Orodispersible Tramadol Tablet (Tradonal Odis®) as Analgesia for Hysterosalpingography Completed NCT00893412 Phase 4
24 Ketamine For Acute Treatment of Pain in Emergency Department Completed NCT02306759 Phase 4
25 Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist Completed NCT01673594 Phase 4
26 Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
27 Counseling for Primary Care Office-based Buprenorphine Completed NCT00595764 Phase 4
28 Naltrexone Treatment for Alcoholic Women Completed NCT00000448 Phase 4
29 A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4
30 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4
31 Buprenorphine and Integrated HIV Care Completed NCT00317460 Phase 4
32 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4
33 Pharmacogenetic Response to Naltrexone For Alcohol Dependence Completed NCT00831272 Phase 4
34 Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice Completed NCT00007527 Phase 4
35 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4
36 Starting Treatment With Agonist Replacement Therapies (START) Completed NCT00315341 Phase 4
37 Multimodal Pain Management for Cesarean Delivery Recruiting NCT02922985 Phase 4
38 Structured Discontinuation vs Continued Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioids for Chronic Pain Recruiting NCT02741076 Phase 4
39 Extended Release Naltrexone for Opioid-Dependent Youth Recruiting NCT01843023 Phase 4
40 Buprenorphine to Improve HIV Care Engagement and Outcomes (BRAVO) Recruiting NCT01936857 Phase 4
41 Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain Recruiting NCT02680847 Phase 4
42 Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry Recruiting NCT01999946 Phase 4
43 Neurocognitive Effects of Opiate Agonist Treatment Recruiting NCT01733693 Phase 4
44 Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users Recruiting NCT02445339 Phase 4
45 Project OOPEN: Opioid Overdose Prevention, Education and Intervention Active, not recruiting NCT01788306 Phase 4
46 Effect of Acetazolamide on Central Sleep Apnea Related to Opium Consumption Enrolling by invitation NCT02371473 Phase 4
47 Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection Not yet recruiting NCT03057847 Phase 4
48 Dextromethorphan Use in Multimodal Analgesia Regimens for Total Knee Arthroplasty Not yet recruiting NCT02987920 Phase 4
49 Conversion to Embeda With Rescue Trial Terminated NCT01179191 Phase 4
50 Anxiety in Recovering Opiate Dependence Terminated NCT00668265 Phase 4

Search NIH Clinical Center for Opioid Abuse

Genetic Tests for Opioid Abuse

Anatomical Context for Opioid Abuse

MalaCards organs/tissues related to Opioid Abuse:

39
Heart, B Cells, Brain

Publications for Opioid Abuse

Articles related to Opioid Abuse:

(show top 50) (show all 215)
id Title Authors Year
1
Prescription opioid abuse in prison settings: A systematic review of prevalence, practice and treatment responses. ( 28086177 )
2017
2
Collaboration Needed: Pain Care and Opioid Abuse. ( 27681886 )
2017
3
Prescription opioid abuse and misuse: gap between primary-care investigator assessment and actual extent of these behaviors among patients with chronic pain. ( 27782769 )
2017
4
Hospitalizations Related To Opioid Abuse/Dependence And Associated Serious Infections Increased Sharply, 2002-12. ( 27140989 )
2016
5
New federal law aims to stem opioid abuse. ( 27543569 )
2016
6
Psychoactive substance use prior to the development of iatrogenic opioid abuse: A descriptive analysis of treatment-seeking opioid abusers. ( 27544696 )
2016
7
Common Sense: Use All Proven Pain Methods in a Comprehensive Strategy to Prevent Opioid Abuse. ( 27617879 )
2016
8
A Community Partnership to Respond to the Heroin and Opioid Abuse Epidemic. ( 27012943 )
2016
9
Identifying and assessing the risk of opioid abuse in patients with cancer: an integrative review. ( 27330340 )
2016
10
Profile of female patients seeking in-patient treatment for prescription opioid abuse from a tertiary care drug dependence treatment centre from India. ( 26997020 )
2016
11
Considerations of prescription opioid abuse and misuse among older adults in West Virginia--An Under-Recognized Population at Risk. ( 27301154 )
2016
12
The opioid abuse epidemic: How healthcare helped create a crisis. ( 27078918 )
2016
13
Mitigation Strategies for Opioid Abuse. ( 27406369 )
2016
14
Congress and Federal Agencies Address Opioid Abuse Epidemic, But Will New Initiatives Be Successful? ( 27504065 )
2016
15
The Effect of an Abuse-Deterrent Opioid Formulation on Opioid Abuse-Related Outcomes in the Post-Marketing Setting. ( 27170195 )
2016
16
Opioid Abuse. ( 27566461 )
2016
17
Costs and Work Loss Burden of Diagnosed Opioid Abuse Among Employees on Workers Compensation or Short-term Disability. ( 27820758 )
2016
18
Mitigation Strategies for Opioid Abuse. ( 27406367 )
2016
19
Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic. ( 27530870 )
2016
20
A Guide for Pain Management in Low and Middle Income Communities. Managing the Risk of Opioid Abuse in Patients with Cancer Pain. ( 26973529 )
2016
21
The Surgeon's Role in Stemming the Prescription Opioid Abuse Epidemic. ( 27566462 )
2016
22
State Prescription Drug and Opioid Abuse Task Force Releases Findings and Recommendations. ( 27120959 )
2016
23
Development and preliminary validation of the Opioid Abuse Risk Screener. ( 28070401 )
2016
24
Preventing Chronic Nonmalignant Pain: A Family Physician's Response to the Opioid Abuse Crisis. ( 27669066 )
2016
25
A Tool to Assess Risk of De Novo Opioid Abuse or Dependence. ( 26968469 )
2016
26
The Opioid Abuse Blame Game. ( 27007582 )
2016
27
President Obama Proposes $1.1 Billion in New Funding to Address the Prescription Opioid Abuse and Heroin Use Epidemic. ( 27301690 )
2016
28
Association of Overall Opioid Prescriptions on Adolescent Opioid Abuse. ( 27596964 )
2016
29
AMA Task Force to Reduce Opioid Abuse. Patients with a substance use disorder need treatment--not stigma. ( 27263172 )
2016
30
Doctors must play a leading role in winning the battle against opioid abuse. ( 27526476 )
2016
31
Opioid Abuse in Chronic Pain--Misconceptions and Mitigation Strategies. ( 27028915 )
2016
32
Evaluation of US Federal Legislation for Opioid Abuse: 1973-2016. ( 27585641 )
2016
33
Why a proven tool to combat opioid abuse is underutilized by healthcare professionals. ( 27333702 )
2016
34
A Proactive Response to Prescription Opioid Abuse. ( 26845291 )
2016
35
The Surgeon's Roles in Stemming the Prescription Opioid Abuse Epidemic. ( 27156949 )
2016
36
Mitigation Strategies for Opioid Abuse. ( 27406368 )
2016
37
AMA Task Force to Reduce Opioid Abuse. Patients with a substance use disorder need treatment--not stigma. ( 27301150 )
2016
38
Prescription Opioid Abuse and its Potential Role in Gross Dental Decay. ( 27492482 )
2016
39
A comparison of an opioid abuse screening tool and prescription drug monitoring data in the emergency department. ( 26743334 )
2016
40
Rates of Neonatal Abstinence Syndrome Amid Efforts to Combat the Opioid Abuse Epidemic. ( 27669331 )
2016
41
Drug availability adjustments in population-based studies of prescription opioid abuse. ( 28000295 )
2016
42
Managing Opioid Abuse in Older Adults: Clinical Considerations and Challenges. ( 27027362 )
2016
43
Gender difference in prescription opioid abuse: A focus on oxycodone and hydrocodone. ( 27107788 )
2016
44
Characteristics of High-Cost Patients Diagnosed with Opioid Abuse. ( 26402390 )
2015
45
The Burden of Undiagnosed Opioid Abuse Among Commercially Insured Individuals. ( 25929289 )
2015
46
Preventing prescription opioid abuse. ( 25756449 )
2015
47
Prescription Opioid Abuse: Problems and Responses. ( 25871819 )
2015
48
Preventing prescription opioid abuse. ( 25756450 )
2015
49
Sociodemographic profile and pattern of opioid abuse among patients presenting to a de-addiction centre in tertiary care Hospital of Kashmir. ( 26229346 )
2015
50
Primary Care Physicians' Knowledge And Attitudes Regarding Prescription Opioid Abuse and Diversion. ( 26102320 )
2015

Variations for Opioid Abuse

Expression for Opioid Abuse

Search GEO for disease gene expression data for Opioid Abuse.

GO Terms for Opioid Abuse

Cellular components related to Opioid Abuse according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.91 CCKAR CCKBR DRD2 GRIN3B MAPK10 OPRM1
2 neuronal cell body GO:0043025 9.5 CCK GRIN3B PDYN
3 axon GO:0030424 9.33 CCK DRD2 OPRM1
4 axon terminus GO:0043679 9.26 DRD2 PDYN
5 perikaryon GO:0043204 9.13 CCK DRD2 OPRM1
6 dendrite GO:0030425 8.92 CCK DRD2 OPRM1 PDYN

Biological processes related to Opioid Abuse according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.88 CCK CCKAR CCKBR DRD2 MAPK10 OPRM1
2 forebrain development GO:0030900 9.56 CCKAR DRD2
3 excitatory postsynaptic potential GO:0060079 9.55 GRIN3B OPRM1
4 digestion GO:0007586 9.54 CCKAR CCKBR
5 response to cocaine GO:0042220 9.52 DRD2 OPRM1
6 response to morphine GO:0043278 9.51 DRD2 OPRM1
7 axonogenesis GO:0007409 9.5 CCK CCKAR DRD2
8 regulation of sensory perception of pain GO:0051930 9.49 CCK OPRM1
9 negative regulation of adenylate cyclase activity GO:0007194 9.48 DRD2 OPRM1
10 eating behavior GO:0042755 9.46 CCK OPRM1
11 response to light stimulus GO:0009416 9.43 DRD2 MAPK10
12 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.43 CCKAR CCKBR OPRM1
13 behavioral response to ethanol GO:0048149 9.37 DRD2 OPRM1
14 feeding behavior GO:0007631 9.33 CCKAR CCKBR DRD2
15 cholecystokinin signaling pathway GO:0038188 8.96 CCKAR CCKBR
16 sensory perception GO:0007600 8.8 CCKBR OPRM1 PDYN

Molecular functions related to Opioid Abuse according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.56 CCKAR CCKBR DRD2 OPRM1
2 signal transducer activity GO:0004871 9.26 CCKAR CCKBR DRD2 OPRM1
3 neuropeptide hormone activity GO:0005184 9.16 CCK PDYN
4 cholecystokinin receptor activity GO:0004951 8.62 CCKAR CCKBR

Sources for Opioid Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....